 |
0 Diseases |  |
14 Trials |
|
14 Trials |  |
139 News |  |
| «12345» |
- ||| sabatolimab (MBG453) / Novartis, nisevokitug (NIS793) / Novartis, Ilaris (canakinumab) / Novartis
Enrollment open: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS (clinicaltrials.gov) - Apr 28, 2021
P1, N=90, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting
- || sabatolimab (MBG453) / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases: Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 28, 2021
P1/2, N=252, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> May 2021 | Trial primary completion date: Dec 2021 --> May 2021
- || sabatolimab (MBG453) / Novartis, spartalizumab (PDR001) / Novartis
Enrollment closed, Combination therapy: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (clinicaltrials.gov) - Apr 23, 2021
P1b, N=243, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2021 --> May 2021 | Trial primary completion date: Dec 2021 --> May 2021 Recruiting --> Active, not recruiting
- ||||| sabatolimab (MBG453) / Novartis, spartalizumab (PDR001) / Novartis, PDR001 / Novartis
Sabatolimab (Anti-TIM-3) with or without Spartalizumab (Anti-PD-1) in advanced solid tumors @curijoey @FordePatrick @ANaingMD and colleagues published @CCR_AACR @AACR @OncoAlert https://t.co/90zIHSNpvf (Twitter) - Apr 22, 2021
- ||||| sabatolimab (MBG453) / Novartis, spartalizumab (PDR001) / Novartis, PDR001 / Novartis
Clinical, Combination therapy: Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors https://t.co/Eoyy3pY5jY (Twitter) - Apr 21, 2021
- || sabatolimab (MBG453) / Novartis
New P2 trial: MBG453 in Lower Risk MDS (clinicaltrials.gov) - Apr 1, 2021
P2, N=20, Not yet recruiting, Sponsor: Massachusetts General Hospital
- |||| sabatolimab (MBG453) / Novartis
New P2 trial, Combination therapy: STIMULUS-MDS3: A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (clinicaltrials.gov) - Mar 23, 2021
P2, N=76, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| sabatolimab (MBG453) / Novartis, nisevokitug (NIS793) / Novartis, Ilaris (canakinumab) / Novartis
New P1 trial: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS (clinicaltrials.gov) - Mar 22, 2021
P1, N=90, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| sabatolimab (MBG453) / Novartis
$NVS sabatolimab (anti Tim-3) pivotal trial data due 2023 (Twitter) - Jan 26, 2021
- | Enrollment change, Trial withdrawal: Study of Select Combinations in Adults With Myelofibrosis (clinicaltrials.gov) - Jan 12, 2021
P1, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=195 --> 0 | Recruiting --> Withdrawn
- ||| sabatolimab (MBG453) / Novartis
Sabatolimab + HMA in HR #MDS and #AML #ASH20 (Twitter) - Dec 9, 2020
- ||||| sabatolimab (MBG453) / Novartis
Clinical: Great summary of Phase Ib/ 2 study in HR MDS /AML and it’s findings. Novel TIM-3 antibody Sabatolimab being studied in randomized Phase 2 and 3 studies . Check out https://t.co/sFJ6M1UWGp for MOA details.#ASH20 #mdssm @andrewbrunner @Dr_AmerZeidan (Twitter) - Dec 7, 2020
- ||||| sabatolimab (MBG453) / Novartis
CONGRESS | #ASH20 | Sabatolimab (anti-TIM-3 on immune and leukemic cells) is safely combined with HMAs: TEAEs were consistent with those reported with HMA alone. Promising durable response rates in HR-#MRD, #AML, and #CMML. By @andrewbrunner @MGHCancerCenter #mdssm #leusm (Twitter) - Dec 7, 2020
- |||| sabatolimab (MBG453) / Novartis
The update by @andrewbrunner #ASH20 from Ph1/2 study of anti-TIM3 Sabatolimab (MBG453) with HMA in HR-MDS continues to show ongoing responses with ORR 64% including 23% CR which were durable & low AE profile including low rate of IRAEs supporting the ongoing large STIMULUS trials (Twitter) - Dec 7, 2020
- ||||| sabatolimab (MBG453) / Novartis
Clinical: 637: MDS session,Phase IB study of HMA+Sabatolimab (TIM-3 Ab): improved ORR ct HMA historical data. Durable responses, several pts moving to HSCT, no evidence of inc severe immune AEs and no inc GVHD( mostly Gr 1/2) in pts s/p HSCT.Check out https://t.co/sFJ6M1UWGp for MOA #ASH20 (Twitter) - Dec 7, 2020
- ||| sabatolimab (MBG453) / Novartis
PK/PD data: $NVS High-/Low-Dose Sabatolimab Exhibit Comparable Pharmacokinetics in MDS and AML https://t.co/fo6tg5QfBJ via @targetedonc (Twitter) - Dec 6, 2020
- ||| sabatolimab (MBG453) / Novartis
Looking forward to your presentation tomorrow- all of us fellow PIs are excited about Sabatolimab and other emerging therapies for MDS and AML #mdssm #leusm #ASH20 #ASHTogether @Dr_AmerZeidan (Twitter) - Dec 6, 2020
- |||| sabatolimab (MBG453) / Novartis
PK/PD data: Sabatolimab Showcases Similar Pharmacokinetics Across 400- and 800-mg Doses in MDS/AML @AlfredHealth @MonashUni @ASH_hematology #ASH20 #leusm https://t.co/yvTYbIufoH (Twitter) - Dec 6, 2020
- ||| sabatolimab (MBG453) / Novartis
Clinical: It is exciting to see a number of agents more forward in MDS - and getting early randomized data in the near future! Hopefully we are on the cusp of real changes in the entire treatment of MDS - I am excited to share how sabatolimab may have a role tomorrow at #ASH20 (Twitter) - Dec 6, 2020
- |||| sabatolimab (MBG453) / Novartis
See thread discussing novel TIM-3 antibody Sabatolimab in combo with HMA ( and Ven) in MDS and AML - updated Phase IB data by @andrewbrunner #ASH20. Watch https://t.co/sFJ6M1UWGp @NovartisScience to see MOA. As a PI on study, can say combo was safe without typical IO SE. (Twitter) - Dec 6, 2020
- ||| Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment change: ADORE: Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (clinicaltrials.gov) - Nov 30, 2020
P1/2, N=240, Recruiting, Sponsor: Novartis Pharmaceuticals
N=195 --> 0 | Recruiting --> Withdrawn N=130 --> 240
- |||| sabatolimab (MBG453) / Novartis
New P1/2 trial: STIMULUS-AML2: Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. (clinicaltrials.gov) - Nov 9, 2020
P1/2, N=59, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- sabatolimab (MBG453) / Novartis
[VIRTUAL] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study (Channel 15 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4447;
P1b
These results support TIM-3 as a potential therapeutic target and provide a basis for further development of sabatolimab + HMA in pts with AML or higher-risk MDS. Co-senior authors Uma Borate and Andrew H. Wei contributed equally to the work.
- Jakafi oral (ruxolitinib) / Novartis, Incyte
[VIRTUAL] Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3795;
P1/2
Planned enrollment for the study with the current 3 combinations is 130 pts. Enrollment is currently ongoing.
- sabatolimab (MBG453) / Novartis
[VIRTUAL] Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2656;
P1/2, P1b
No clear relationship was seen between sabatolimab dose or steady state exposure and safety/efficacy at the doses tested. These results support clinical development of the sabatolimab 400 mg Q2W and 800 mg Q4W dosing regimens.
- sabatolimab (MBG453) / Novartis
[VIRTUAL] The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML) (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1082;
P1b, P2, P
Part 1 consists of a safety run-in (≈18 pts) across 2 escalating sabatolimab dose levels (400/800 mg IV Q4W on D8 of each 28-d cycle) in combination with Aza (75 mg/m2 IV/SC on D1-D7, or D1-D5 + D8 and D9) and venetoclax 400 mg PO QD. If this triple combination is assessed to be safe, part 2 (expansion) will open and enroll approximately 68 additional pts who will receive sabatolimab 800 mg Q4W in combination with Aza and venetoclax.
- ||| Enrollment open: Study of Select Combinations in Adults With Myelofibrosis (clinicaltrials.gov) - Nov 4, 2020
P1, N=195, Recruiting, Sponsor: Novartis Pharmaceuticals
If this triple combination is assessed to be safe, part 2 (expansion) will open and enroll approximately 68 additional pts who will receive sabatolimab 800 mg Q4W in combination with Aza and venetoclax. Not yet recruiting --> Recruiting
- ||| sabatolimab (MBG453) / Novartis, spartalizumab (PDR001) / Novartis
Enrollment closed, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Nov 3, 2020
P1/2, N=252, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || sabatolimab (MBG453) / Novartis, siremadlin (HDM201) / Novartis
Trial completion date, Trial primary completion date, Combination therapy: HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Nov 3, 2020
P1, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Apr 2021 --> Dec 2021
- MBG453 / Novartis
[VIRTUAL] Dual modes of action for anti-TIM-3 antibody MBG453 in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity () - Oct 14, 2020 - Abstract #SITC2020SITC_1469;
P1b
Further studies are ongoing to determine: (1) whether MBG453 can mediate physiologically relevant ADCP of TIM-3-expressing leukemic cells; and (2) the potential of MBG453 to impact the autocrine feedback loop of TIM-3/Galectin-9. Ethics Approval The human tissue used in these studies was under the Novartis Institutes of BioMedical Research Ethics Board IRB, Approval Number 201252867.
- MBG453 / Novartis
[VIRTUAL] Dual modes of action for anti-TIM-3 antibody MBG453 in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity () - Oct 14, 2020 - Abstract #SITC2020SITC_734;
P1b
Further studies are ongoing to determine: (1) whether MBG453 can mediate physiologically relevant ADCP of TIM-3-expressing leukemic cells; and (2) the potential of MBG453 to impact the autocrine feedback loop of TIM-3/Galectin-9. Ethics Approval The human tissue used in these studies was under the Novartis Institutes of BioMedical Research Ethics Board IRB, Approval Number 201252867.
- | sabatolimab (MBG453) / Novartis
Trial completion date, Combination therapy: STIMULUS-MDS1: A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (clinicaltrials.gov) - Oct 7, 2020
P2, N=127, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Ethics Approval The human tissue used in these studies was under the Novartis Institutes of BioMedical Research Ethics Board IRB, Approval Number 201252867. Trial completion date: Sep 2023 --> Aug 2024
- || sabatolimab (MBG453) / Novartis
Enrollment closed, Trial primary completion date, Combination therapy: STIMULUS-MDS1: A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (clinicaltrials.gov) - Sep 28, 2020
P2, N=127, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2023 --> Aug 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2021 --> Sep 2023
- MBG453 / Novartis, azacitidine / Generic mfg., decitabine / Generic mfg.
[VIRTUAL] Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study () - Sep 14, 2020 - Abstract #SOHO2020SOHO_371;
P1b
MBG453 plus Dec or Aza was safe and well tolerated in HR-MDS and AML, with TEAEs consistent with that for single-agent HMA. Both combinations showed encouraging response rates and emerging durability.
- MBG453 / Novartis, azacitidine / Generic mfg., decitabine / Generic mfg.
[VIRTUAL] The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia () - Sep 14, 2020 - Abstract #SOHO2020SOHO_370;
P1b, P2
Part 1 is a safety run-in (n≈18) across 2 MBG453 dose levels (400/800 mg IV D8 of each 28-day cycle) plus AZA (75 mg/m2 IV/SC D1–D7, or D1–D5, D8-D9) and venetoclax 400 mg PO QD. If the triplet is assessed to be safe, Part 2 (expansion; n≈68) will investigate MBG453 at 800 mg Q4W in combination with AZA+venetoclax.
- || sabatolimab (MBG453) / Novartis, spartalizumab (PDR001) / Novartis
Enrollment open, Combination therapy: Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM (clinicaltrials.gov) - Aug 7, 2020
P1, N=15, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
If the triplet is assessed to be safe, Part 2 (expansion; n≈68) will investigate MBG453 at 800 mg Q4W in combination with AZA+venetoclax. Active, not recruiting --> Recruiting
- azacitidine / Generic mfg.
[VIRTUAL] The Problem of TP53-Mutant MDS/AML () - Jul 14, 2020 - Abstract #SOHO2020SOHO_124;
P1, P1b, P
In TP53 mutant AML, azacitidine in combination with venetoclax did achieve an increased CR/CRi rate of 47%, although these patients had a short median duration of CR/CRi of 5.6 months and a median OS of 7.2 months, similar to survival outcome data with single agent HMA, with recent data showing TP53 as a major driver of resistance to venetoclax.12, 13 This combination is ongoing in MDS patients (NCT02942290)...Other novel HMA combinations have recently had high ORR/CR rates as frontline therapy, which include MBG453 and pevonedistat, although molecular subset data in TP53 mutant patients are unclear...The treatment landscape of these patients is encouraging, as the combination of azacitidine with APR-246 or magrolimab have been well tolerated and produced significantly improved response rates. Ideally, future translational data will further elucidate the underpinnings driving the poor outcomes for this molecular subgroup to lead to additional novel therapeutic strategies.
- ||||| MBG453 / Novartis
Clinical: [Next Pharma] @Novartis TIM-3 monoclonal antibody MBG453 was approved for clinical use in #China. #pharmaceuticals #ChinaPharma (Twitter) - Jul 8, 2020
- || Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion date, Trial primary completion date: ADORE: Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (clinicaltrials.gov) - Jul 7, 2020
P1/2, N=130, Recruiting, Sponsor: Novartis Pharmaceuticals
Ideally, future translational data will further elucidate the underpinnings driving the poor outcomes for this molecular subgroup to lead to additional novel therapeutic strategies. Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Mar 2023 --> Jan 2024
- ||| sabatolimab (MBG453) / Novartis
Enrollment open, Combination therapy: STIMULUS-AML-1: A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (clinicaltrials.gov) - Jun 23, 2020
P2, N=86, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Mar 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- |||| MBG453 / Novartis
Interview: @VJHemOnc spoke to @beatalleukemia of @OHSUNews about the use of MBG453 with #HMA in high-risk #MDS and #AML Check out the interview at: 👉https://t.co/O6t355ne18👈 @EHA_Hematology #EHA25Virtual #EHA25 #HemOnc #MDSsm #CTsm #ImmunoOnc #Leusm #Leukemia #EHAtrending (Twitter) - Jun 18, 2020
- |||||| sabatolimab (MBG453) / Novartis
Enrollment open, Trial primary completion date, Combination therapy: STIMULUS-MDS2: Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (clinicaltrials.gov) - Jun 1, 2020
P3, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2023 --> Sep 2027
- azacitidine / Generic mfg.
[VIRTUAL] HOW TO BETTER DEFINE EVENT-FREE SURVIVAL IN A CLINICAL TRIAL WITH AML PATIENTS NOT TOLERATING INTENSIVE CHEMOTHERAPY? () - May 16, 2020 - Abstract #EHA2020EHA_2086;
P2
It describes in a structured and consistent way how we define and measure the treatment effect of interest and how we deal with situations that could impact the treatment outcome. It helps to find clinically sound solutions for situations where operational challenges do not allow to follow an ideal strategy of an estimand like following patients for disease assessments after HSCT in this study.
- MBG453 / Novartis, azacitidine / Generic mfg., decitabine / Generic mfg.
[VIRTUAL] THE STIMULUS CLINICAL TRIAL PROGRAM: EVALUATING COMBINATION THERAPY WITH MBG453 IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR-MDS) OR ACUTE MYELOID LEUKEMIA (AML) () - May 16, 2020 - Abstract #EHA2020EHA_2050;
P1b, P2
Results None, trials in progress. Conclusion None, trials in progress.
- MBG453 / Novartis, azacitidine / Generic mfg., decitabine / Generic mfg.
[VIRTUAL] POST-TRANSPLANT OUTCOMES OF PATIENTS WITH MDS AND AML AFTER RECEIVING HYPOMETHYLATING AGENT THERAPY COMBINED WITH THE TIM-3 INHIBITOR, MBG453 () - May 16, 2020 - Abstract #EHA2020EHA_1444;
P1b
Escalating doses of MBG453 were administered i.v. every 2 weeks (Q2W; days 8, 22) or every four weeks (Q4W; day 8) in combination with decitabine (20 mg/m2; i.v. days 1–5) or azacitidine (75 mg/m2; i.v. days 1-7)...9 patients received decitabine+MBG453, one also received the anti-PD1 antibody spartalizumab...One patient with therapy-related TP53 mutated MDS harboring a complex karyotype relapsed at day +134; this patient died from sepsis during salvage chemotherapy. Conclusion Patients treated with the anti-TIM3 antibody MBG453 in combination with HMA for MDS and AML can successfully proceed to allogeneic transplant; to date there are limited toxicities related to GVHD.
- MBG453 / Novartis, azacitidine / Generic mfg., decitabine / Generic mfg.
[VIRTUAL] ANTI-TIM-3 ANTIBODY MBG453 IN COMBINATION WITH HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): A PHASE 1 STUDY () - May 16, 2020 - Abstract #EHA2020EHA_510;
P1b
Both combinations showed antileukemic activity with encouraging response rates and emerging durability, supporting further development of MBG453 combined with HMAs in MDS/AML. (A Brunner & AH Wei contributed equally)
- || sabatolimab (MBG453) / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (clinicaltrials.gov) - May 13, 2020
P1b, N=235, Recruiting, Sponsor: Novartis Pharmaceuticals
(A Brunner & AH Wei contributed equally) Trial completion date: Apr 2021 --> Nov 2021 | Trial primary completion date: Apr 2020 --> Nov 2021
- || sabatolimab (MBG453) / Novartis, spartalizumab (PDR001) / Novartis
Enrollment closed, Combination therapy: Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM (clinicaltrials.gov) - Apr 2, 2020
P1, N=15, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Apr 2021 --> Nov 2021 | Trial primary completion date: Apr 2020 --> Nov 2021 Recruiting --> Active, not recruiting
- || sabatolimab (MBG453) / Novartis, spartalizumab (PDR001) / Novartis
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy: Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM (clinicaltrials.gov) - Mar 6, 2020
P1, N=15, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Feb 2024 | Trial primary completion date: Jun 2021 --> Feb 2022